Observational study on Hepatitis B reactivation in patients using TDF or Entekavir
Efficacy of TDF and Entekavir Prophylaxis at Hepatitis B Reactivation: Multi Center Retrospective Study
This study looks at patients taking Entekavir or TDF to see how often they experience Hepatitis B reactivation while using these medications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Viral Hepatitis Society Academic / other |
| Locations | 1 site (Istanbul) |
| Trial ID | NCT06049602 on ClinicalTrials.gov |
What this trial studies
This observational study examines patients who have received Entekavir or TDF for the prophylaxis of Hepatitis B. It is a retrospective multi-center analysis that aims to gather data on the incidence of Hepatitis B reactivation among these patients. By analyzing historical patient records, the study seeks to identify patterns and outcomes related to the use of these antiviral medications. The findings could provide insights into the effectiveness of these treatments in preventing Hepatitis B reactivation.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 18 and older who have used Entekavir or TDF for Hepatitis B prophylaxis.
Not a fit: Patients under 18 years old will not benefit from this study as they are excluded from participation.
Why it matters
Potential benefit: If successful, this study could enhance understanding of Hepatitis B management and improve prophylactic strategies for at-risk patients.
How similar studies have performed: While this study is observational and retrospective, similar studies have shown success in understanding the dynamics of Hepatitis B reactivation in patients on antiviral therapy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients used entekavir or TDF for Hepatitis B prophylaxis Exclusion Criteria: * Patients lower then 18 years old.
Where this trial is running
Istanbul
- Cerrahpasa Medical Faculty — Istanbul, Turkey (Recruiting)
Study contacts
- Study coordinator: Fehmi Tabak, Prof
- Email: fehmitabak@yahoo.com
- Phone: +905322763788
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.